A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer

European Urology

Volumn 70, Issue 1, 2016, Pages 35-41

  Yoshimura, Kazuhiro ^a   Minami, Takafumi ^a   Nozawa, Masahiro ^a   Kimura, Takahiro ^b   Egawa, Shin ^b   Fujimoto, Hiroyuki ^c   Yamada, Akira ^d   Itoh, Kyogo ^d   Uemura, Hirotsugu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KURUME UNIVERSITY   (Japan)

Author keywords

Castration resistant prostate cancer; Low dose dexamethasone; Peptide vaccine immunotherapy

Indexed keywords

DEXAMETHASONE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A3 ANTIGEN; IMMUNOGLOBULIN G; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; HLA A ANTIGEN; HLA-A*02 ANTIGEN; HLA-A*03 ANTIGEN; SUBUNIT VACCINE;

ADULT; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; KAPLAN MEIER METHOD; LOCAL SKIN REACTION; LOG RANK TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOON FACE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ACTIVE IMMUNOTHERAPY; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROCEDURES; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HLA-A24 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; PRECISION MEDICINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; VACCINES, SUBUNIT;

EID: 84983189665     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.12.050     Document Type: Article

References (28)

1. [1] Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
2. [2] Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
3. [3] De Bono, J.S., Oudard, S., Ozguroglu, M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
4. [4] Kantoff, P.W., Higano, C.S., Shore, N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363 (2010), 411–422.
5. [5] Ryan, C.J., Smith, M.R., Fizaki, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CUA-AA-302): final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16 (2015), 152–160.
6. [6] Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371 (2014), 424–433.
7. [7] Noguchi, M., Uemura, H., Naito, S., et al. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71 (2011), 470–479.
8. [8] Uemura, H., Fujimoto, K., Mine, T., et al. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci 101 (2010), 601–608.
9. [9] Noguchi, M., Kakuma, T., Uemura, H., et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 59 (2010), 1001–1009.
10. [10] Naito, M., Itoh, K., Komatsu, N., et al. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate 68 (2008), 1753–1762.
11. [11] Nishimura, K., Nonomura, N., Yasunaga, Y., et al. A low dose of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89 (2000), 2570–2576.
12. [12] Storlie, J.A., Buckner, J.C., Wiseman, G.A., et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Urology 52 (1998), 252–256.
13. [13] Yano, A., Fujii, Y., Iwai, A., Kageyama, Y., Kihara, K., Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12 (2006), 3003–3009.
14. [14] Nishimura, K., Nonomura, N., Satoh, E., et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93 (2001), 1739–1746.
15. [15] Bubley, G.J., Carducci, M., Dahut, W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17 (1999), 3461–3467.
16. [16] Noguchi, M., Kobayashi, K., Suetsugu, N., et al. Cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone refractory prostate cancer patients by peptide vaccination. Prostate 57 (2003), 80–92.
17. [17] Noguchi, M., Itoh, K., Suekane, S., et al. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci 95 (2004), 77–84.
18. [18] Noguchi, M., Itoh, K., Suekane, S., et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 60 (2004), 32–45.
19. [19] Small, E.J., Schellhammer, P.F., Higano, C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006), 3089–3099.
20. [20] Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28 (2010), 1099–1105.
21. [21] Gulley, J.A., Madan, R.A., Tsang, K.Y., et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2 (2014), 133–141.
22. [22] McNeel, D.G., Dunphy, E.J., Davies, J.G., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27 (2009), 4047–4054.
23. [23] Kübler, H., Maurer, T., Stenzl, A., et al. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA [abstract 4535]. J Clin Oncol, 29(Suppl), 2011.
24. [24] Spisek, R., Podrazil, M., Babjuk, M., et al. Phase I/II clinical trials of dendritic cell-based immunotherapy in patients with the biochemical relapse of the prostate cancer [abstract 16002]. J Clin Oncol, 31(Suppl), 2013.
25. [25] Venkitaraman, R., Lorente, D., Murthy, V., et al. A randomized phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67 (2015), 673–679.
26. [26] Halabi, S., Lin, C.Y., Kelly, W.K., et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32 (2014), 671–677.
27. [27] Hoos, A., Eggermont, A.M., Janetzki, S., et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102 (2010), 1388–1397.
28. [28] Noguchi, M., Moriya, F., Suekane, S., et al. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. BMC Cancer 13 (2013), 613–623.